Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.
2.

Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection.

Pariser DM, Wendelken ME, Rycerz AM Jr, Gellings Lowe N, Yost JM, Lipner SR.

J Drugs Dermatol. 2018 Feb 1;17(2):168-172.

PMID:
29462224
3.

Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole

Pollak RA, Ilie C.

J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273.

PMID:
29240863
4.

Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.

Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T.

J Drugs Dermatol. 2017 Oct 1;16(10):1016-1021.

PMID:
29036255
5.
6.

A financial perspective on the topical treatment of onychomycosis.

Lagrew JP.

J Am Acad Dermatol. 2016 Jul;75(1):e37. doi: 10.1016/j.jaad.2015.11.053. No abstract available.

PMID:
27317544
7.

Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.

Elewski BE, Aly R, Baldwin SL, González Soto RF, Rich P, Weisfeld M, Wiltz H, Zane LT, Pollak R.

J Am Acad Dermatol. 2015 Jul;73(1):62-9. doi: 10.1016/j.jaad.2015.04.010. Epub 2015 May 5.

8.

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT.

J Drugs Dermatol. 2014 Sep;13(9):1124-32.

PMID:
25226015

Supplemental Content

Loading ...
Support Center